Glaucoma is not a single disease — it is a group of progressive optic neuropathies characterised by the gradual degeneration of retinal ganglion cells (RGCs) and their axons, which form the optic nerve. Left untreated, it leads to irreversible vision loss and blindness. It is the leading cause of irreversible blindness worldwide, affecting over 80 million people, and is particularly insidious because it is largely asymptomatic until significant damage has already occurred.
The most common form — primary open-angle glaucoma (POAG) — progresses silently over years. By the time a patient notices peripheral vision loss, up to 40% of retinal ganglion cells may already be lost. This makes early detection and proactive management — including nutritional support — critically important.
How the Eye Works — The Basics
To understand glaucoma, you need to understand intraocular pressure (IOP). The eye is filled with a clear fluid called aqueous humour, which is continuously produced by the ciliary body and drained through the trabecular meshwork at the angle where the iris meets the cornea. This fluid maintains the eye's shape and nourishes the lens and cornea.
When drainage is impaired or production is excessive, fluid builds up and intraocular pressure (IOP) rises. Elevated IOP compresses the optic nerve at the lamina cribrosa — a sieve-like structure at the back of the eye — disrupting axonal transport, reducing blood flow to the optic nerve head, and triggering a cascade of neurodegeneration.
Normal IOP is 10–21 mmHg. Glaucoma is typically diagnosed when IOP exceeds 21 mmHg, though critically, normal-tension glaucoma (NTG) — where optic nerve damage occurs despite normal IOP — accounts for up to 30–40% of cases, particularly in Asian populations. This tells us that IOP is not the whole story.
Types of Glaucoma
Primary Open-Angle Glaucoma (POAG)
The most common form. The drainage angle remains open but the trabecular meshwork becomes progressively less efficient, causing IOP to rise slowly over years. Painless and asymptomatic until late stages. Risk factors include age over 60, family history, elevated IOP, African or Hispanic ancestry, myopia, and thin central corneal thickness.
Angle-Closure Glaucoma
The iris physically blocks the drainage angle, causing a sudden and dramatic rise in IOP. Acute angle-closure is a medical emergency — presenting with severe eye pain, headache, nausea, blurred vision, and halos around lights. Requires immediate treatment to prevent permanent vision loss. More common in hyperopic (far-sighted) eyes and in Asian populations.
Normal-Tension Glaucoma (NTG)
Optic nerve damage occurs despite IOP within the normal range. The primary mechanisms are thought to be vascular insufficiency (poor blood flow to the optic nerve), increased susceptibility of RGCs to apoptosis, and autoimmune factors. Strongly associated with systemic vascular conditions including low blood pressure, Raynaud's phenomenon, and sleep apnoea.
Secondary Glaucomas
Glaucoma arising from another condition — including pseudoexfoliation syndrome (the most common identifiable cause of open-angle glaucoma worldwide), pigment dispersion syndrome, uveitis, trauma, or steroid use.
The Molecular Mechanisms of Optic Nerve Damage
Mechanical Compression
Elevated IOP compresses the optic nerve axons at the lamina cribrosa, physically blocking anterograde and retrograde axonal transport. This deprives RGCs of neurotrophic factors (particularly BDNF — brain-derived neurotrophic factor) that they depend on for survival, triggering apoptosis.
Vascular Insufficiency
The optic nerve head has a precarious blood supply. Elevated IOP reduces ocular perfusion pressure (the difference between mean arterial pressure and IOP), compromising blood flow to the optic nerve. In NTG, systemic vascular dysregulation — including vasospasm and endothelial dysfunction — is the primary driver even without elevated IOP.
Oxidative Stress
The retina is one of the most metabolically active tissues in the body and is highly vulnerable to oxidative damage. Elevated IOP and ischaemia generate reactive oxygen species (ROS) that damage RGC mitochondria, lipid membranes, and DNA. Glutathione levels in the aqueous humour are significantly reduced in glaucoma patients. Oxidative stress also damages the trabecular meshwork, impairing drainage and further elevating IOP — a vicious cycle.
Neuroinflammation
Activated microglia and astrocytes in the optic nerve head release pro-inflammatory cytokines (TNF-α, IL-1β, IL-6) that are directly toxic to RGCs. TNF-α in particular has been shown to induce RGC apoptosis independently of IOP. Complement system activation also contributes to synapse elimination and neurodegeneration in glaucoma.
Excitotoxicity
Ischaemia and oxidative stress cause excessive release of glutamate in the retina. Overstimulation of NMDA receptors on RGCs leads to calcium influx, mitochondrial dysfunction, and cell death — a process called excitotoxicity. This is a key mechanism in both IOP-dependent and IOP-independent glaucoma progression.
Mitochondrial Dysfunction
RGC axons are among the longest in the body and are heavily dependent on mitochondrial energy production for axonal transport. Mitochondrial dysfunction — driven by oxidative stress, ischaemia, and ageing — impairs ATP production, disrupts calcium homeostasis, and triggers the intrinsic apoptosis pathway. Emerging research identifies glaucoma as fundamentally a mitochondrial disease in many cases.
Conventional Medical Treatments
The cornerstone of conventional glaucoma management is lowering intraocular pressure — the only proven disease-modifying intervention in standard care. However, IOP reduction does not halt progression in all patients (particularly NTG), highlighting the need for neuroprotective strategies.
Eye Drops — First-Line Medications
Prostaglandin analogues (latanoprost, bimatoprost, travoprost) are the most commonly prescribed first-line agents. They increase uveoscleral outflow of aqueous humour, reducing IOP by 25–35%. Applied once daily, they are generally well tolerated though can cause iris pigmentation changes and periorbital fat loss with long-term use.
Beta-blockers (timolol, betaxolol) reduce aqueous humour production by blocking beta-2 receptors on the ciliary body. Timolol is non-selective and can cause systemic effects including bradycardia, bronchospasm, and fatigue. Betaxolol is cardioselective and may have additional neuroprotective properties via calcium channel blockade.
Carbonic anhydrase inhibitors (dorzolamide, brinzolamide topically; acetazolamide orally) reduce aqueous production by inhibiting the enzyme carbonic anhydrase in the ciliary body. Oral acetazolamide is highly effective but poorly tolerated long-term due to systemic side effects including paraesthesia, fatigue, kidney stones, and electrolyte disturbances.
Alpha-2 agonists (brimonidine) reduce aqueous production and increase uveoscleral outflow. Brimonidine also has direct neuroprotective properties — it crosses the blood-retinal barrier and activates alpha-2 receptors on RGCs, reducing glutamate excitotoxicity and promoting cell survival. This makes it particularly valuable in NTG.
Rho kinase inhibitors (netarsudil) are a newer class that increase trabecular outflow by relaxing the trabecular meshwork and Schlemm's canal. They also reduce episcleral venous pressure and may have direct neuroprotective effects.
Laser Treatments
Selective Laser Trabeculoplasty (SLT) uses a low-energy laser to selectively target pigmented trabecular meshwork cells, stimulating a biological response that improves drainage. It is now recommended as a first-line treatment in many guidelines, with effects lasting 3–5 years and repeatable. It is safe, effective, and avoids the compliance issues of daily eye drops.
Laser peripheral iridotomy (LPI) is the definitive treatment for angle-closure glaucoma — a small hole is created in the iris to allow aqueous to bypass the pupillary block and reach the drainage angle.
Surgical Interventions
Trabeculectomy creates a new drainage pathway (bleb) under the conjunctiva, bypassing the trabecular meshwork entirely. It is highly effective at lowering IOP but carries risks of infection, hypotony, and bleb failure. Minimally invasive glaucoma surgery (MIGS) — including devices such as iStent, Hydrus, and XEN gel stent — offers a safer surgical option with more modest IOP reduction, often performed in combination with cataract surgery.
Nutritional & Neuroprotective Support
Conventional treatment focuses almost exclusively on IOP reduction. But given the roles of oxidative stress, vascular insufficiency, neuroinflammation, and mitochondrial dysfunction in glaucoma pathogenesis, targeted nutritional support offers a meaningful adjunctive strategy — particularly for neuroprotection and slowing progression.
Niacinamide (Vitamin B3) — Mitochondrial Neuroprotection
Niacinamide (nicotinamide) has emerged as one of the most exciting nutritional interventions in glaucoma research. Its primary mechanism is the restoration of NAD+ (nicotinamide adenine dinucleotide) — a critical coenzyme for mitochondrial energy production that declines significantly with age and in glaucomatous RGCs.
RGCs are among the most energetically demanding cells in the body. As NAD+ levels fall, mitochondrial ATP production falters, axonal transport fails, and RGCs become increasingly vulnerable to IOP-related stress and apoptosis. Niacinamide directly replenishes NAD+ via the salvage pathway, restoring mitochondrial function and RGC resilience.
Key clinical evidence:
- Williams et al. (2017) — Cell: Niacinamide prevented RGC loss and optic nerve degeneration by up to 93% in glaucoma mouse models — the landmark study that catalysed human trials.
- Hui et al. (2020) — Clinical & Experimental Ophthalmology: Randomised, double-blind, placebo-controlled trial in 57 glaucoma patients. High-dose niacinamide (3g/day) significantly improved inner retinal function (PERG) over 12 weeks — the first RCT demonstrating functional neuroprotection in human glaucoma.
- Tribble et al. (2021) — Redox Biology: Niacinamide protects RGC axons by maintaining mitochondrial membrane potential and reducing oxidative stress in the optic nerve head.
- De Moraes et al. (2022): Ongoing phase 2/3 trials investigating niacinamide as a neuroprotective adjunct to IOP-lowering therapy, with promising interim results.
Dose: 1.5–3g/day in divided doses. Start at 500mg twice daily and titrate up. Use niacinamide (nicotinamide) — not niacin/nicotinic acid, which causes flushing and is a different compound.
Mirtogenol® — IOP Reduction & Ocular Blood Flow
Mirtogenol® is a patented combination of Mirtoselect® (bilberry extract, 36% anthocyanins) and Pycnogenol® (French maritime pine bark, 65–75% procyanidins), acting synergistically on multiple glaucoma mechanisms.
Mechanisms: Pycnogenol inhibits ACE and reduces endothelin-1, improving trabecular outflow. Both components enhance nitric oxide production, improving optic nerve blood flow. Anthocyanins and procyanidins provide potent antioxidant protection to RGCs and the trabecular meshwork. Pycnogenol also inhibits NF-κB, reducing TNF-α and IL-1β — cytokines directly toxic to RGCs.
Key clinical evidence:
- Steigerwalt et al. (2008) — Journal of Ocular Pharmacology and Therapeutics: RCT in 38 early POAG patients. Mirtogenol® reduced IOP from 25.2 mmHg to 22.2 mmHg after 3 months — a clinically meaningful 3 mmHg reduction — with no significant change in controls. Ocular blood flow velocity also improved significantly.
- Steigerwalt et al. (2010) — Molecular Vision: Mirtogenol® significantly improved retinal blood flow in ocular hypertension patients, measured by colour Doppler imaging.
- Combination with latanoprost: Adding Mirtogenol® to latanoprost eye drops produced greater IOP reduction than latanoprost alone — supporting its use as an adjunct to conventional treatment.
Dose: 80mg Mirtoselect® + 40mg Pycnogenol® daily. Effects typically seen within 4–8 weeks. Well tolerated with no significant adverse effects in clinical trials.
Magnesium — Vascular & Neuroprotective
Magnesium is a natural calcium channel blocker and vasodilator. In glaucoma — particularly NTG — it improves ocular blood flow by relaxing vascular smooth muscle and reducing vasospasm. A clinical study found that magnesium supplementation significantly improved visual field indices in NTG patients over 4 weeks. Magnesium also inhibits NMDA receptor-mediated excitotoxicity, directly protecting RGCs from glutamate toxicity. It is one of the most evidence-backed nutritional interventions for glaucoma.
We recommend RN Labs Magnesium Glycinate 180c or Magnesium Glycinate 180c for optimal bioavailability and tolerability. Designs For Health Magnesium Glycinate Complex 60caps is an excellent practitioner-grade option.
Omega-3 Fatty Acids — Anti-Inflammatory & Neuroprotective
EPA and DHA reduce neuroinflammation in the optic nerve, support retinal ganglion cell survival, and improve ocular blood flow. DHA is the predominant structural fatty acid in the retina and is essential for photoreceptor membrane integrity. Epidemiological studies show that higher dietary omega-3 intake is associated with reduced glaucoma risk. Omega-3s also reduce TNF-α and IL-1β — cytokines directly toxic to RGCs — and promote the production of specialised pro-resolving mediators (SPMs) that actively resolve neuroinflammation.
Pro-Resolve Omega is the most targeted option for neuroinflammation resolution. O.N.E. Omega provides a high-potency daily dose of EPA and DHA. For plant-based support, Algae Omega and Lifestream Vegan Omega-3 are excellent choices.
Ginkgo Biloba — Circulation & Neuroprotection
Ginkgo biloba is one of the most studied botanicals for glaucoma. Its mechanisms include improving microcirculation to the optic nerve head, inhibiting platelet-activating factor (reducing vasospasm), scavenging free radicals, and directly protecting RGCs from oxidative and excitotoxic damage. Multiple clinical trials have demonstrated improvements in visual field parameters in NTG patients taking standardised ginkgo extract (EGb 761, 120–240mg daily). It is particularly relevant for NTG and vascular-type glaucoma.
Doctor's Best Extra Strength Ginkgo 120mg 120 Veggie Caps provides a standardised, high-potency extract suitable for clinical use.
Alpha Lipoic Acid (ALA) — Mitochondrial & Antioxidant Support
Alpha lipoic acid is a potent mitochondrial antioxidant that is both fat- and water-soluble, allowing it to protect cell membranes and aqueous compartments simultaneously. It regenerates vitamins C and E and boosts intracellular glutathione. In glaucoma, ALA protects RGC mitochondria from oxidative damage, reduces excitotoxicity, and has been shown in clinical studies to improve visual function in glaucoma patients. It also chelates heavy metals that can accumulate in the trabecular meshwork and impair drainage.
We stock Alpha Lipoic Acid 200mg and Doctor's Best Alpha-Lipoic Acid 600mg 60 vcaps for higher therapeutic doses. Doctor's Best Benfotiamine 150 + Alpha-Lipoic Acid 300mg combines ALA with benfotiamine for enhanced mitochondrial support.
Vitamin C — Aqueous Humour & Antioxidant
Vitamin C is present in the aqueous humour at concentrations 20–50 times higher than in plasma — suggesting a critical role in protecting the anterior segment from oxidative damage. It supports collagen synthesis in the trabecular meshwork and sclera, regenerates glutathione, and has been shown to reduce IOP in some studies. Liposomal delivery maximises absorption and bioavailability.
Liposomal Vitamin C, Coyne Biomax Liposomal Vitamin C, and Natroceutics Lipo Vitamin C Complete 30 caps are our top recommendations for high-absorption vitamin C support.
NAC (N-Acetyl Cysteine) — Glutathione & Neuroprotection
NAC is the direct precursor to glutathione — the primary antioxidant defence in the retina and aqueous humour. Glaucoma patients consistently show reduced glutathione levels in the aqueous humour and trabecular meshwork. NAC replenishes glutathione, reduces oxidative damage to RGCs and the trabecular meshwork, and inhibits NLRP3 inflammasome activation — reducing neuroinflammatory cytokine production. It also has direct neuroprotective effects against glutamate excitotoxicity.
Designs For Health N-Acetyl-L-Cysteine 120vc is a practitioner-grade option. NOW NAC 600mg 100VC and CodeAge Liposomal NAC+ Platinum 120c offer excellent value and enhanced delivery respectively.
Vitamin D — Neuroprotection & Immune Modulation
Vitamin D receptors are expressed on retinal ganglion cells, and vitamin D deficiency is associated with increased glaucoma risk in epidemiological studies. Vitamin D promotes RGC survival, reduces neuroinflammation by suppressing Th1/Th17 activity and microglial activation, and modulates the complement system — which is implicated in synapse loss in glaucoma. Deficiency is common in NZ populations, particularly in winter.
Vitamin D3 Liquid allows flexible therapeutic dosing. Doctor's Best Vitamin D3 1000IU 180 Softgel is a reliable daily maintenance option.
Lifestyle Factors That Affect Glaucoma
Exercise
Regular moderate aerobic exercise (brisk walking, cycling, swimming) has been shown to reduce IOP by 2–5 mmHg and improve ocular perfusion pressure. A large prospective study found that higher physical activity levels were associated with a significantly reduced risk of glaucoma. Conversely, certain exercises — particularly head-down yoga poses, heavy weightlifting with breath-holding (Valsalva manoeuvre), and playing wind instruments — can transiently spike IOP and should be approached with caution.
Sleep Position
IOP is higher when lying down than when sitting upright, and is highest in the early morning hours — which correlates with the time of greatest glaucoma progression. Sleeping with the head slightly elevated (20–30 degrees) can reduce nocturnal IOP spikes. Sleeping on the side with the more affected eye facing down also increases IOP in that eye and should be avoided where possible.
Caffeine
Caffeine transiently raises IOP by 1–3 mmHg for 1–2 hours after consumption. While moderate coffee consumption has not been definitively linked to glaucoma progression in most studies, patients with poorly controlled IOP or NTG may benefit from moderating intake.
Hydration
Drinking large volumes of fluid rapidly (more than 500ml in a short period) can transiently raise IOP. Patients should sip fluids steadily throughout the day rather than drinking large amounts at once.
Stress Management
Psychological stress activates the sympathetic nervous system, increasing cortisol and catecholamines that can raise IOP and reduce ocular blood flow. Chronic stress is associated with worse glaucoma outcomes. Mindfulness, breathwork, and adequate sleep are important adjuncts to medical management.
When to See a Practitioner
Glaucoma is a serious, progressive condition that requires professional diagnosis and monitoring. If you experience any of the following, seek urgent ophthalmological assessment:
- Sudden severe eye pain, headache, nausea, or vomiting
- Sudden blurred vision or halos around lights
- Gradual loss of peripheral (side) vision
- A family history of glaucoma — particularly in a first-degree relative
- Age over 60, or over 40 with additional risk factors
Routine eye pressure checks and optic nerve assessment should be part of regular eye examinations from age 40 onwards. Optical coherence tomography (OCT) of the optic nerve and retinal nerve fibre layer is the gold standard for detecting early structural damage before visual field loss occurs.
Summary
Glaucoma is a complex, multifactorial optic neuropathy driven by elevated IOP, vascular insufficiency, oxidative stress, neuroinflammation, excitotoxicity, and mitochondrial dysfunction. Conventional treatment centres on IOP reduction through eye drops, laser, and surgery — and remains essential. But nutritional and neuroprotective strategies targeting the underlying mechanisms offer meaningful adjunctive support, particularly for normal-tension glaucoma and patients with ongoing progression despite controlled IOP.
Magnesium, omega-3 fatty acids, ginkgo biloba, alpha lipoic acid, vitamin C, NAC, and vitamin D are among the most evidence-backed nutritional tools for supporting optic nerve health and slowing glaucomatous neurodegeneration.
Always consult a qualified ophthalmologist or healthcare practitioner for diagnosis, monitoring, and treatment of glaucoma. Nutritional supplements are adjunctive support only and do not replace prescribed medical treatment.